nach oben

Medical Microbiology and Immunology

Erschienen in:

01.11.2004 | Original Investigation

Miltefosine (Impavido): the first oral treatment against leishmaniasis

verfasst von: H. Sindermann, S. L. Croft, K. R. Engel, W. Bommer, H. J. Eibl, C. Unger, J. Engel

Erschienen in: Medical Microbiology and Immunology | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

Achterberg V, Gercken G (1987) Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastogotes. Mol Biochem Parasitol 23:117–122CrossRefPubMed

Achterberg V, Gercken G (1987) Metabolism of ether lyophospholipids in Leishmania donovani promastigotes. Mol Biochem Parasitol 26:277–287CrossRefPubMed

Berman JD (1991) Biological mechanisms of clinical antileishmanial agents: a review. J Cell Pharmacol 2:85–82

Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684–703PubMed

Bryceson ADM, Chulay JD, Ho M, Mugambii M, Were JB (1985) Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 79:700–704PubMed

Bryceson ADM (1987) Therapy in man. In: Peters W, Killick-Kendrick R (eds) The leishmaniasis in biology and medicine, Vol 2. Academic Press, New York, pp 848–907

Burdzy K, Munder PG, Fischer H, Westphal O (1964) Steigerung der Phagozytose von Perionialmagrophagen durch Lysolecithin. Z Naturforsch 19B:1118

Croft SL, Neal RA, Pendergast W, Chan JH (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633–2636CrossRefPubMed

Croft SL, Neal RA, Thornton E, Herrmann DBJ (1993) Antileishmanial activity of the ether phospholipid ilmofosine. Trans R Soc Trop Med Hyg 87:217–219

10.

Croft SL, Snowdon D, Yardley V (1996) The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38:1041–1047PubMed

11.

Davidson RN, Di Martino L, Gradoni L, Giacchino R (1994) Liposomal amphotericin B (Am Bisome) in Mediteranian visceral leishmaniasis: a multicenter trial. Q J Med 87:75–81PubMed

12.

Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drug 56:1009–1018

13.

Desjeux P (1996) Leishmaniasis: public health aspects and control. Clin Dermatol 14:417–423CrossRefPubMed

14.

Dietze R, Milan EP, Berman JD, Grogl M (1993) Treatment of Brazilian Kala-Azar with a short course of Amphocil (Amphotericin B-chlolesterol dispersion). Clin Infect Dis 17:981–986PubMed

15.

Dogra J (1991) A double-blind study on the efficacy of oral Dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 85:212–213PubMed

16.

Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45:1872–1875CrossRefPubMed

17.

Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH₃ (edelfosine) and amphotericin B. Acta Trop 81:151–157CrossRefPubMed

18.

Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK (1994) Successful treatment of resistant visceral Leishmaniasis with liposomal Amphotericin B. Trans R Soc Trop Med Hyg 88:228PubMed

19.

Grevelink SA, Lerner EA (1996) Leishmaniasis. J Am Acad Dermatol 34:257–272PubMed

20.

Grogl M, Oduola AMJ, Cordero LDC, Kyle DE (1989) Leishmania spp: development of Pentostam resistant clones in vitro by discontinuous drug exposure. Exp Parasitol 69:78–90PubMed

21.

Harms G, Zwingenberger K, Sandkamp B, Omena S, Pedrosa C, Richter J, Rosenkaimer F (1993) Immunochemotherapy of visceral leishmaniasis. A pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony. J Interferon Res 13:39–41PubMed

22.

Hepburn NC, Nolan J, Fenn L, Herd RM, Neilson JMM (1994) Cardiac effects of sodium stibogluconate. Q J Med 87:465–472

23.

Herwaldt BL (1999) Miltefosine—the long-awaited therapy for visceral leishmaniasis? N Engl J Med 341:1840–1842CrossRefPubMed

24.

Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl HJ, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18506). Eur J Cancer Clin Oncol 24:1457–1461PubMed

25.

Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T (1991) Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J Cancer Res Clin Oncol 117:403–408PubMed

26.

Hochhuth CH, Vehmeyer K, Eibl HJ, Unger C (1992) Hexadecylphosphocholine induces interferone-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 141:161–168PubMed

27.

Jha TK, Giri YN, Singh TK, Jha S (1995) Use of amphotericin B in drug resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg 52:536–538PubMed

28.

Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795–1800CrossRefPubMed

29.

Klenner T, Beckers T, Nooter K, Holtmann H (1996) Influence of hexadecylphosphocholine (Miltefosine) on cytokine synthesis and biological responses. Adv Exp Med Biol 416:181–187PubMed

30.

Kuhlencord A, Maniera T, Eibl H, Unger C (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36:1630–1634PubMed

31.

Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, Kubar J (1998) Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 42:654–658PubMed

32.

Lira R, Sundar S, Makharia A, et al (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony resistantstrains of Leishmania donovani. J Infect Dis 180:564CrossRefPubMed

33.

Lira R, Contreras LM, Santa-Rita RM, Urbina JA (2001) Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of the in-vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537–546CrossRefPubMed

34.

Lux H, Hart DT, Parker PJ, Klenner T (1996) Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for antileishmanial alkyl phospholipid analogues. Adv Exp Med Biol 416:201–211PubMed

35.

Lux H, Heise N, Klenner T, Hart D, Opperdoes FR (2000) Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 111:1–14CrossRefPubMed

36.

McBride M, Linney M, Claydon EJ, Weber J (1994) Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis 19:362PubMed

37.

Murray HW, Squires KE, Harms G, Rosenkaimer F (1992) Clinical trials of interferon-gamma for leishmaniasis. In: Sonnenfeld G, Czarniecki C, Nacy C, et al (eds) Cytokines and resistance to nonviral infections. Biomedical Press, Augusta, pp 199–206

38.

Murray HW (2000) Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 44:3235–3236CrossRefPubMed

39.

Murray HW, Delph-Etienne S (2000) Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 181:795–799CrossRefPubMed

40.

Safa O, Parkin SM, Matthew AM, Bibby MC (1997) Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res 17:37–44PubMed

41.

Santa-Rita RM, Barbosa HS, Meirelles MNSL, Castro SL de (2000) Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 75:219–228CrossRefPubMed

42.

Schmidt-Ott R, Klenner T, Overath P, Aebischer T (1999) Topical treatment with hexadecylphosphocholine (Miltex^®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 93:85–90PubMed

43.

Soto J, Toledo J, Gutierrez P, Nicholis RS, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001) Treatment of American cutaneous leishmaniasis with Miltefosine, an oral agent. Clin Infect Dis 33:E57–E61CrossRefPubMed

44.

Squires KE, Rosenkaimer F, Sherwood JA, Were JBO, Murray HW (1993) Immunochemotherapy for visceral Leishmaniasis. A controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 48:666–669PubMed

45.

Sundar S, Rosenkaimer F, Murray HW (1994) Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis 170:659–662PubMed

46.

Sundar S, Rosenkaimer F, Lesser ML, Murray HW (1995) Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis J Infect Dis 171:992–996

47.

Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW (1998) Trial of miltefosine for visceral leishmaniasis. Lancet 352:1821–1823CrossRefPubMed

48.

Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW (1999) Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93:589–597CrossRefPubMed

49.

Sundar S, Makharia A, More DK, Agraval G, Voss A, Fischer C, Bachmann P, Murray HW (2001) Short course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31:1110–1113CrossRef

50.

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739–1746

51.

Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J (2003) Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 22:434–438CrossRefPubMed

52.

Teklemariam S, Hiwot AG, Frommel D, Miko TL (1994) Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88:334–339PubMed

53.

Thakur CP, Kumar M, Pandey AK (1991) Evaluation of efficacy of longer durations of therapy for fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 92:103–120

54.

Thakur CP, Olliaro P, Gothoskar S, Bhowmick S (1992) Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycine)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86:615–616PubMed

55.

Tsushima S, Yoshioka Y, Tanida S, Nomura H, Nojima S, Hozumi M (1982) Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem Pharm Bull (Tokyo) 30:3260–3270

56.

Unger C, Maniera T, Kaufmann-Kolle P, Eibl H (1998) In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 34 (Suppl F):133–140

57.

Verweij J, Plating A, Berg M van der, Stoter G (1992) A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118:606–608PubMed

58.

Wilcocks C, Manson-Bahr PEC (1972) Manon's tropical diseases. Baillière Tindall, London, pp 119–133

Titel: Miltefosine (Impavido): the first oral treatment against leishmaniasis
verfasst von: H. Sindermann
S. L. Croft
K. R. Engel
W. Bommer
H. J. Eibl
C. Unger
J. Engel
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: Medical Microbiology and Immunology / Ausgabe 4/2004
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-003-0201-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis

An ospA-polymerase chain reaction/restriction fragment length polymorphism-based method for sensitive detection and reliable differentiation of all European Borrelia burgdorferi sensu lato species and OspA types

The functional interaction between CD98 and CD147 in regulation of virus-induced cell fusion and osteoclast formation

Thrombin induces Sp1-mediated antiviral effects in cytomegalovirus-infected human retinal pigment epithelial cells

Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus